This study looks at the risks and benefits of active surveillance (AS) compared to guideline-concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low-risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life outcomes compared to GCC.
NCT# 02926911
